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Abstract ERA is an essential GTPase widely conserved in
bacteria. Homologues of ERA are also present in higher
eukaryotic cells. ERA is involved in bacterial cell cycle control
at a point preceding cell division. In order to aid the functional
investigation of ERA and to facilitate structure-function studies,
we have undertaken the X-ray crystallographic analysis of this
protein. Here, we report the purification and crystallization
procedures and results. The purified ERA exhibits nucleotide-
binding activity and GTP-hydrolytic activity. ERA is one of the
very few multi-domain GTPases crystallized to date.
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1. Introduction
ERA is a small GTPase (ca. 35 kDa in Escherichia coli)
ubiquitously found in bacteria [1] and is essential for bacterial
viability [2,3]. ERA homologues are also found in some higher
eukaryotic organisms, such as Antirrhinum [4], mouse and
human [5]. The sequences from polygenetic sources are highly
homologous [6,5], e.g. the sequences from human and bacteria
share nearly 30% identity and 53% similarity [5]. The sequence
of the N-terminal GTPase domain is closely related to those
found in Ras proteins [7,8], GK [9] and EF-Tu [10], while the
C-terminal sequence is unique. The ability of ERA from other
bacterial species to cross-complement ERA lethal mutants in
E. coli [1,11] suggests common functions of the protein among
genetically distant species.
Studies have shown that the expression of ERA in E. coli is
positively correlated with the cell growth rate [5]. The ERA
homologue, ERG, in Antirrhinum is most strongly expressed
in dividing cells and metabolically active cells [4]. Limiting
ERA expression in E. coli resulted in cells with two or four
nucleoids arrested in the cell cycle just before cytokinesis
[12,13]. Similar cellular e¡ects were observed for a mutant
ERA with impaired GTPase activity [12]. Therefore, ERA is
believed to play a role in cell cycle control and the coupling of
cell growth rate with cell division [5,13]. Morphologically,
ERA’s action on cell cycle progression appears to be at a
point after chromosome partitioning but before cytokinesis.
This is supported by genetic studies that reduced ERA activity
in E. coli suppresses normally lethal mutations in DNA rep-
lication and chromosome partitioning, but does not suppress
temperature-sensitive lethal mutations in cell division [5].
However, the exact mechanism by which ERA signals growth
and division remains unknown.
Recent sequence analysis indicates that ERA contains an
RNA-binding KH domain in its C-terminal region (S. Mian,
personal communication). Support that ERA may be directly
involved in translation comes from the fact that the gene for
16S rRNA dimethyltransferase functions as a multicopy sup-
pressor for a cold-sensitive mutant of ERA [14]. Mutations in
either the N- or C- terminal domain cause severe defects in
cell growth [11,15].
The lack of structural information of ERA has limited the
progress towards unraveling its function. Since ERA is essen-
tial for viability in bacteria, including the pathogens, it is an
important target for antimicrobial drug design, where struc-
tural information is crucial. In this study, we report the puri-
¢cation, characterization and crystallization of ERA from E.
coli.
2. Materials and methods
2.1. Expression
Cloning of ERA from E. coli W3110 was previously described [16].
To over-express ERA from TAP106 (pCE31), a 5 ml overnight-grown
L-broth culture containing 100 Wg/ml ampicillin was used to inoculate
500 ml of the same medium. The cells were grown with shaking at 200
rpm/min at 32‡C until an OD600 = 0.5 was reached. Then, the cells
were transferred to 40‡C and grown for another 2 h. The cells were
quickly chilled in ice-water and harvested by centrifugation at
10 000Ug for 10 min. The pellet was washed with TMD bu¡er con-
taining 20% sucrose before being frozen by dry-ice and stored at
370‡C.
2.2. Cell lysis
The cell pellet was allowed to thaw on ice for 3 h. A lysis bu¡er (50
mM Tris-HCl, pH 8, 200 mM NaCl, 10 mg/ml lysozyme, 1 mM
RNase A) was added to the pellet in 3:1 (v/w) ratio. A protease
inhibitor cocktail was added to reach a ¢nal concentration of 100
Wg/ml PMSF (Sigma), 40 Wg/ml Bestatin (Amreco), 10 Wg/ml E-64
(Amreco) and 1 mM EDTA (Sigma). The bacterial pellet was sus-
pended by a brief sonication, and was incubated on ice for 30 min.
The suspension was then sonicated again in ten 30 s pulses in ice-
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water. The lysate was centrifuged at 15 000Ug for 20 min and the
supernatant containing soluble ERA was collected.
2.3. Polyethyleneimine (PEI) and ammonium sulfate (AS)
precipitation
The following procedures were carried out at 4‡C. 5% PEI solution
(Sigma) (pretitrated to pH 8.0) was added drop-wise to the lysate with
shaking to a ¢nal concentration of 0.35%. After centrifugation at
15 000Ug for 10 min, the soluble portion was isolated. Next, satu-
rated AS solution (pretitrated to pH 8.0) was added drop-wise with
shaking to the solution. The precipitate formed between 0 to 45% AS
was collected.
2.4. Chromatographic puri¢cation
The chromatographic puri¢cation was performed on a BioCad/
SPRINT chromatography system (PerSeptive) equipped with a Gilson
fraction collector.
2.4.1. Anion exchange chromatography. The protein pellet from
the AS precipitation was dissolved and diluted in the starting bu¡er
(50 mM Tris-HCl, pH 8.0) and applied through a 50 ml Superloop
(Pharmacia) to a MonoQ 16/10 column (Pharmacia). The column was
washed with the starting bu¡er and the sample was eluted with a £at
NaCl salt gradient (40^140 mM in 50 ml bu¡er) at a £ow rate of 4 ml/
min.
2.4.2. Hydrophobic interaction chromatography. The sample was
diluted to match the salt concentration of the starting bu¡er (50
mM Tris-HCl, pH 8.0, 2.5 M NaCl) and loaded to the Superloop.
The sample was applied to a phenyl Superose 10/10 column (Pharma-
cia) and washed with the 1.5 M NaCl before being eluted in a decreas-
ing salt gradient from 1.5 M to zero salt in 12 ml bu¡er at a £ow rate
of 1 ml/min.
2.4.3. A⁄nity chromatography. A self-packed GDP-agarose (from
Sigma, GDP immobilized onto beaded agarose through an 11-atom
spacer to ribose hydroxyls) column (5 mmU10 mm) was used. The
sample was bu¡er exchanged to the starting bu¡er (50 mM Tris-HCl,
pH 8.0) using an Amicon concentrator (10k, Amicon) and loaded to
the column. A 0^1 M NaCl elution gradient in 50 ml bu¡er at a £ow
rate of 3 ml/min was used.
2.4.4. Gel ¢ltration chromatography. The sample was concentrated
to less than 200 Wl in the running bu¡er (50 mM Tris-HCl, pH 8.0,
150 mM NaCl, unless speci¢ed otherwise) and injected to a Superdex
75 10/30 column (Pharmacia). The sample was eluted isocratically
using the running bu¡er. The column was calibrated using a SEC
molecular weight standard kit from Bio-Rad. The calibration data
¢t to a straight line with r2s 0.999.
2.5. GTPase activity assay
Puri¢ed ERA (5 WM) was incubated with varying concentrations of
cold GTP in TMD bu¡er containing 100 mM NaCl, 0.5 mg/ml BSA
in the presence of 0.43 WM (0.4 WCi) [K-32P]GTP (Amersham) for 30
min at room temperature. Aliquots (1 Wl) were spotted onto a PEI-
cellulose TLC plate (Aldrich) and let run for 2 h in a bu¡er containing
0.5 M KH2PO4 and 1 M NaCl. Spots for radioactive GTP and GDP
on the plate were visualized and measured o¡ the phosphor screen
(after 16 h exposure) using a phosphor imaging system (Storm 820
from Molecular Dynamics). Cold GTP hydrolysis was calculated
based on the ratio of hot GDP/GDP+GTP after subtracting sponta-
neous GTP hydrolysis from a negative control.
2.6. Protein N-terminal sequencing
Polypeptides were separated by preparative SDS-PAGE using a
self-cast Tris-glycine gel (12%) with 10 mmU2 mm wells. After being
stained with Coomassie blue, polypeptide bands were transferred to a
nylon membrane through standard technique [17]. Bands on the mem-
brane were then cut out and used for N-terminal sequencing as pre-
viously described [16].
2.7. Crystallization and heavy atom derivative preparation
The hang-drop vapor di¡usion technique was used. Initial crystal-
lization screen as well as additive and detergent screens were pre-
formed using screen kits from Hampton Research. Heavy atom com-
pounds used to prepare derivatives were from the following sources:
ethylmercury phosphate, Noah Technologies; 2-amino phenylmercu-
ric acetate, ICN Biochemicals; uranyl acetate, Aldrich. X-ray di¡rac-
tion data were collected with a MarResearch imaging plate system
with mirrors using Cu KK radiation from a Rigaku rotating anode
operated at 50 kV and 100 mA. Data collections were done at 100 K
maintained by an Oxford Cryosystems. Di¡raction data were proc-
essed with HKL2000 [18].
2.8. Other procedures
For mass spectroscopy puri¢ed ERA was analyzed using Hewlett-
Packard 1100 series LC/MSD under the electrospray mode. ERA
concentration was determined using Bradford [19] and BCA [20]
methods with reagent kits from Pierce. Unless speci¢ed otherwise,
all the SDS-PAGE analyses were carried out using precast tris-glycine
gels from Novex. Pre-stained molecular weight marker and the silver-
staining kit were also from Novex.
3. Results
3.1. Protein expression and puri¢cation
E. coli ERA was expressed under V PL promoter with tem-
perature induction. After a 2 h induction, the expressed ERA
comprised V30% of the total protein based on densitometry
scan of the SDS-PAGE gel. When induced at 40‡C, more than
half of the expressed ERA was soluble (data not shown).
Although the expression level of ERA in wildtype cells is
closely related to growth rate [5], over-expression of ERA
does not a¡ect the cell growth.
The isolation of E. coli ERA from cells was confounded by
serious protease degradation. Without protease protection,
ERA was rapidly degraded in the cell lysate. Even after PEI
and AS precipitation (see below), protease activity was still
signi¢cant. Once degradation has occurred, the ERA frag-
ments were di⁄cult to separate by our chromatographic meth-
ods. PMSF alone or commercial protease inhibitor cocktails
failed to eliminate degradation completely. To determine the
protease cleavage sites, a preparative SDS-PAGE was per-
formed using partially puri¢ed ERA (AS precipitation only)
from unprotected cell lysate. As shown in Fig. 1A, two major
degradation bands (D1 and D2) were observed. The larger
band (D1) has a molecular weight of V30 kDa. N-terminal
sequencing of the two degradation products from the gel (Fig.
1A) revealed that both bands are missing the N-terminal 38
amino acids (cleavage between R38 and K39). If the N-termi-
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Fig. 1. A: SDS-PAGE (12% Tris-Gly) with Coomassie staining of
ERA degradation products using an unprotected sample after the
AS precipitation (see Section 2). The band labels are: WT, wild-
type; D1, degradation band 1 (major); D2, degradation band 2 (mi-
nor). B: SDS-PAGE (12% Tris-Gly) with silver staining of ERA
samples. Lane coding is: M, molecular weight marker; L, crude ly-
sate; P, supernatant after PEI precipitation; AS, pellet after AS pre-
cipitation; A1 and A2, peaks A and B from AEC (Fig. 2A), respec-
tively; H, after HIC puri¢cation.
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nal cleavage is the only part missing in band D1, it would
have a calculated molecular weight of 29 718 Da, very close to
30 kDa, therefore, the C-terminus of band D1 is probably
intact, whereas the minor band D2 has been subjected to
additional C-terminal degradation. N-terminal sequencing of
the wildtype band WT indicated that only the N-terminal
methionine was removed. Mass spectroscopy of puri¢ed
ERA showed a molecular weight of 33 682 þ 5 Da, consistent
with the calculated molecular weight of 33 678 Da. A protease
inhibitor cocktail including PMSF, Bestatin, E-64 and EDTA
was designed to inhibit a wide spectrum of proteases with
each inhibitor prepared to achieve its e¡ective concentration
[21] (see Section 2). This cocktail proved to be e¡ective in
inhibiting protease activity to an undetectable level by the
SDS-PAGE silver staining.
Only soluble ERA in the crude lysate was used for further
puri¢cation; the pellet fraction was discarded. ERA was frac-
tionated from the crude lysate by AS precipitation (0^45%
saturation). The ERA recovered was associated with signi¢-
cant amounts of nucleic acid, which greatly interfered with
later anion exchange chromatography (AEC). Prior precipita-
tion of the lysate by PEI was able to remove most of these
nucleic acids. A ¢nal concentration of 0.35% (v/v) PEI applied
to the crude lysate largely removed nucleic acid without pre-
cipitating ERA. A sequential PEI separation and AS precip-
itation of ERA was used to prepare the sample for further
chromatographic puri¢cation.
Systematic puri¢cation of ERA using combinations of
chromatographic methods, including anionic exchange, size
exclusion, a⁄nity, hydrophobic interaction and cationic ex-
change chromatographies, was investigated. A combination
of anionic exchange and hydrophobic interaction chromatog-
raphies turned out to be e⁄cient and convenient.
The ERA pellet from sequential PEI and AS treatment was
dissolved in a large volume of bu¡er A for AEC and the
sample was loaded onto a MonoQ column (Pharmacia) with-
out dialysis. A very shallow NaCl salt gradient separated the
main ERA peak (peak A in Fig. 2A) from smaller ERA peaks
(peak B in Fig. 2A). The main peak eluting at V100 mM
NaCl is much purer than the ERA peaks eluting at higher
NaCl concentrations as shown from SDS-PAGE in Fig. 1B.
Peak B also contains relatively higher amount of nucleic acid
as indicated by an A280/A260 ratio of 1.26 (Fig. 2A, inset), as
compared to 1.80 of peak A. Peak B also appears to have
more associated impurity proteins. Nevertheless, ERA sam-
ples from peaks A and B exhibit exactly the same molecular
weight from mass spectroscopy. The fractions collected from
AEC were diluted into high salt loading bu¡er for hydropho-
bic interaction chromatography (HIC) and loaded onto a phe-
nyl-Superose column (Pharmacia) without dialysis. ERA
eluted as a single peak (Fig. 2B) with a higher A280/A260 ratio
of 2.16, and was essentially pure as judged by SDS-PAGE
silver staining (Fig. 1B). With the described puri¢cation pro-
cedures, 1 liter of cell culture typically yielded 15 mg of pure
ERA.
3.2. GDP binding of ERA on a⁄nity column
The binding of the puri¢ed ERA to GDP was shown by the
retention of ERA in a GDP-agarose column. AEC-puri¢ed
ERA was loaded onto the a⁄nity column and eluted with a
NaCl gradient from 0 to 1 M. Some ERA did not bind and
came through as peak A in Fig. 3A, while the majority of the
sample (V73%) bound to the GDP-agarose gel and eluted as
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Fig. 2. A: Anion exchange chromatography of ERA. Both peak A and peak B are ERA (see text). Nucleic acid (last peak) is eluted at high
salt. The inset shows an enlargement of peak B to show the relative scales of the A280 and A260. B: Hydrophobic interaction chromatography
of ERA. In both graphs, the salt gradient is indicated by the thin line with the scale on the right vertical axis.
Fig. 3. A: A⁄nity chromatography of ERA by GDP-agarose col-
umn. The salt gradient is indicated by the thin line, while the A280
and A260 are shown in thick black and gray lines, respectively. B:
SDS-PAGE (Coomassie staining) of ERA before and after the puri-
¢cation shown in A. Lane coding is : M, molecular weight marker;
S, sample applied to the column; UB, unbound fractions (peak A);
B, bound fractions (peak B).
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a large peak at V0.05^0.6 M NaCl (peak B). ERA from peak
A, probably already GDP-bound, showed a low A280/A260
ratio of 1.07, and was not able to be retained by the a⁄nity
column, while peak B is presumably a GDP-free form of
ERA. Peak A also contains more impurities than peak B
(Fig. 3B). The relatively large fraction of the putative GDP-
bound form (peak A) may comprise endogenous ERA-GDP
complex as well as complex formed from the association of
ERA with leached GDP from the GDP-agarose gel during
loading.
3.3. The puri¢ed ERA is GTPase-active
The GTPase activity of the puri¢ed ERA was demonstrated
by the hydrolysis of [K-32P]GTP to [K-32P]GDP. GTP and
GDP were separated by TLC and corresponding spots were
measured o¡ the phosphor imaging plate (Fig. 4). The appar-
ent turnover rate (kcat) of ERA GTPase activity is estimated
to be s 0.006 min31 from the last lane in Fig. 4, where the
substrate concentration (40 WM) is much larger than that of
ERA (8 WM). This value is comparable to that reported pre-
viously [16]. The kcat value is probably close to those seen in
Ras proteins [22] and less than that of GKs of heterotrimeric
G-proteins [23], which are known to exhibit an internal
GTPase-activating (GAP) activity [23]. The low kcat value of
ERA may be an intrinsic necessity for this protein to maintain
GTP-bound as Ras proteins.
3.4. The puri¢ed ERA is partially GDP-bound
Freshly puri¢ed ERA showed a single peak at V35 kDa
from size exclusion chromatography (SEC) (Fig. 5, line a).
Aged samples (stored at 320‡C for 4 months) showed a small
peak with high A260 absorbance at a low molecular weight
position in SEC (Fig. 5, line b), which coincides with the
elution time of a GDP control (line c), indicating that GDP
was released from the aged ERA. The di¡erence in the elution
times of GDP (line c) and GTP (line d) controls was well
resolved by the SEC. Since there was no GDP or GTP added
during the preparation, the released GDP appears to be en-
dogenous. Larger amount of nucleotide or nucleic acid could
be released by increasing the salt concentration in the bu¡er
to 1 M Li2SO4 (line e) (the chromatography deviated from the
conventional SEC mechanism by showing elongated retention
times due to the high salt concentration). Sulfate ion competes
with phosphate groups of nucleotides for binding to proteins
and can replace a bound nucleotide (unpublished results). The
ERA-GDP form of ERA present in the crude cell lysate ap-
pears to become unligated gradually during AEC and HIC, as
indicated by the increasing A280/A260 ratio for the ERA peaks
during the puri¢cation.
3.5. Crystallization of ERA
After ERA was puri¢ed by AEC, it was crystallized using
condition no. 16 (0.1 M sodium HEPES, pH 7.5, 1.5 M lith-
ium sulfate) of the Crystal Screen I from Hampton Research.
Crystals grew in about 10 days from the 1:1 mixture of con-
centrated protein (8 mg/ml) and the screening solution. How-
ever, the crystals were clusters of microcrystals, unable to be
used for X-ray di¡raction. Varying the protein concentration
or the precipitant concentration had little e¡ect on the crystal
morphology. Single crystals were not obtained from additive
and detergent screens. Further puri¢cation of the sample with
HIC and a⁄nity chromatography improved the morphology
of the crystal slightly but still not suitable for di¡raction data
collection. Single crystals were eventually obtained by com-
bining AEC with HIC and the addition of 0.8 M NaCl to the
crystallization mixture (Fig. 6). The typical starting equilib-
rium contained 0.1 M Tris-HCl, pH 8.0, 0.8 M lithium sulfate,
0.8 M sodium chloride and 8 mg/ml ERA. The high NaCl
concentration may help to eliminate non-speci¢c ionic inter-
actions in the crystal packing. Single crystals were grown to
near millimeter size using the micro-seeding technique. How-
ever, irrespective of the crystal size, they di¡racted to at best
3.2 Aî resolution. The crystals, in space group P21 with cell
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Fig. 6. The monoclinic crystal of ERA.
Fig. 5. SEC chromatograms of ERA and guanine nucleotide under
di¡erent conditions: a, ERA freshly puri¢ed; b, puri¢ed ERA after
storage at 320‡C for 4 months; c and d, standard GDP and GTP;
e, ERA after treatment with 1 M Li2SO4. The typical SEC bu¡er
used for a^d contains 0.15 M NaCl, while in e, NaCl was replaced
with 1 M Li2SO4. The A280 absorbance is shown in dark lines and
the A260 absorbance where shown is in gray lines.
Fig. 4. Hydrolysis of GTP to GDP by the puri¢ed ERA. The TLC
separation of [K-32P]GTP and [K-32P]GDP is shown. The initial cold
GTP concentration for each reaction is indicated at the bottom. A
negative control (N) without ERA is shown in the ¢rst lane.
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dimensions of a = 86.8 Aî , b = 67.6 Aî , c = 87.3 Aî and
L= 115.8‡, contains 65% solvent (Vm = 3.5 Aî 3/Da, assuming
two molecules in the asymmetric unit). Di¡raction of the crys-
tal was greatly improved to V2.4 Aî by an overnight solvent
exchange with a solution containing 30% sucrose (0.1 M Tris-
HCl, pH 8.0, 1.2 M, Li2SO4, 0.5 M NaCl, 30% sucrose).
Complete di¡raction data were collected at 100 K to 2.4 Aî
resolution with an Rsym of 0.056. Cocrystallizations of ERA
with GDP or non-hydrolyzable GTP analogues (in concentra-
tions of 1^10 mM) were also attempted. The crystals from
cocrystallizations showed no di¡erence in morphology and
cell constants from the apo crystals.
3.6. Heavy atom derivative preparations
To facilitate the structural determination of ERA using
multiple isomorphous replacement (MIR) method, potential
heavy atom derivatives of the crystal were screened. ERA
crystals were soaked in a protection solution (0.1 M Tris-
HCl, pH 8.0, 1.5 M lithium sulfate, 0.8 M sodium chloride,
25% sucrose) containing varying concentrations of heavy
atom compounds (Table 1). Most heavy atom compounds
have very limited solubility (6 0.1 mM) in the protection
solution. Ethyl mercury phosphate (EMP) in either the Tris
bu¡er or HEPES bu¡er resulted in very good Hg derivative.
4-Aminophenylmercuric acetate and uranyl acetate also pro-
vided reasonable derivatives. Complete data sets of the deriv-
atives have been collected.
4. Discussion
Since ERA is an essential protein for every bacterium tested
to date, no null mutations can be isolated, making the study
of its function di⁄cult. Structural studies of ERA are ex-
pected to provide insight into its function, particularly the
structure of the unique C-terminal domain, for which no glob-
al sequence similarity has been identi¢ed.
In this study we successfully puri¢ed E. coli ERA in large
quantity to near homogeneity. More puri¢cation steps were
introduced compared to that reported previously [16], and this
facilitated the crystallization. The puri¢ed ERA is active in
hydrolyzing GTP to GDP with a speci¢c activity comparable
to previous results [16]. The puri¢ed ERA also has GDP
a⁄nity and is partially GDP-bound. However, under the crys-
tallization condition, ERA is probably nucleotide-free, due to
the presence of high concentrations of sulfate ion and NaCl.
Sulfate ion may compete e¡ectively with the phosphate groups
of GDP or GTP for binding to the protein. So far, no sulfate-
free crystallization conditions have been found despite exten-
sive e¡orts.
ERA has recently been suspected to be an RNA-binding
protein based on the presence of an RNA-binding KH do-
main in its C-terminal region (S. Mian, personal communica-
tion). This is supported by the observation that ERA is asso-
ciated with substantial amounts of nucleic acid after
ammonium sulfate precipitation if PEI precipitation is not
performed. The associated nucleic acid is degraded by RNase
A but not DNase I (data not shown). The addition of RNase
A during cell lysis helped to lower the nucleic acid contami-
nation in AEC. The AEC shown here resolved the main peak
of ERA from the second peak much better than the previous
study [16]. We imagine that during puri¢cation from crude
extracts some ERA remain bound to RNA, especially if
RNase is not added. Both RNA-bound and RNA-free ERA
bind to the anionic exchange column with the RNA tightly
bound and eluted at very high salt (V1 M). During the salt
gradient elution, free ERA elutes ¢rst in the main peak and
RNA-bound ERA elutes at higher salt concentrations leaving
most of the column-bound RNA behind. Thus, two peaks of
ERA were detected, which have exactly the same molecular
weight from mass spectroscopy and were indistinguishable in
subsequent analyses. We have always used the ¢rst/major
peak in all studies.
E. coli ERA is highly susceptible to protease degradation.
The major cleavage site, according to sequence alignment with
p21Ras, is around the switch I region of the GTPase domain.
The cleavage totally eliminates the G1 region, and presumably
renders the degradation product unable to bind guanine nu-
cleotides. Small amounts of degraded ERA are usually unde-
tectable by Coomassie-stained SDS-PAGE (data not shown),
and therefore special precautions should be taken by applying
protease inhibitors during all the puri¢cation.
A GTP hydrolysis-coupled conformational switch plays a
wide variety of roles in biological systems. However, there are
very limited number of GTPases in bacteria that have been
structurally characterized. The structural solution of ERA is
expected to add a new member to this short list and in addi-
tion, provide new insight into the functions of this widely
conserved cell cycle regulator.
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